Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BICA THERAPEUTICS INC. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is being conducted by 1 distinct examiner within 1 distinct art unit, reflecting a specific focus for the company's current patent filings. The concentration in 1 distinct art unit suggests that the pending technology is specialized within a particular biological or pharmaceutical classification.
The busiest examiner for the portfolio is ROSSI, JULIA ANNE LORRAIN, who is responsible for 1 pending office action. Because the company's current workload involves only 1 distinct examiner, the prosecution strategy must be responsive to the specific arguments and prior art cited by this individual. With 1 pending office action, the company's immediate success is centralized under this single examiner's review. This arrangement means that the applicant's progress is dependent on the examination style of the 1 distinct examiner identified in the data.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009601 | FUSION PROTEIN CONTAINING ERYTHROPOIETIN POLYPEPTIDE | ROSSI, JULIA ANNE LORRAIN | 12d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18009601 | FUSION PROTEIN CONTAINING ERYTHROPOIETIN POLYPEPTIDE | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112DP | Final Rejection | 12d | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial